Skip to main content

Newsroom press releases

13/10/26 - 13:00

Diasorin obtained FDA approval for Human Parvovirus B19 IgM and IgG on the Liaison XL (334.34 KB)
Products Immunodiagnostic
Download

02/10/26 - 14:22

Margherita Sacerdoti appointed Investor Relations & ESG Senior Director at Diasorin (151.77 KB)
Other
Download

31/07/26 - 12:50

Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
Financial Data
Download

19/06/26 - 15:45

Diasorin Announces FDA 510(K) Clearance and CLIA Waiver for the LIAISON NES Group A Streptococcus (GAS) Assay (174.02 KB)
Products Molecular
Download

20/05/26 - 11:16

Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
Financial Data
Download

19/05/26 - 19:23

Diasorin Receives 510(K) Clearance for Fully Customizable LIAISON PLEX Gastrointestinal Flex Assay (179.61 KB)
Products Molecular
Download

08/05/26 - 17:54

Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
Financial Data
Download

04/05/26 - 17:45

Diasorin Strengthens its Leadership of Immuno Division with the Appointment of Gabriele Allegri as President (158.42 KB)
Other
Download

29/04/26 - 15:52

Shareholders' Meeting 2026 (166.06 KB)
Other
Download

07/04/26 - 10:05

Communication on total amount of voting rights (7 April 2026) (225.44 KB)
Other
Download

25/03/26 - 12:04

Publication of the document for the Ordinary Shareholders' Meeting scheduled on April 29, 2026 (181.97 KB)
Financial Disclosures
Download

20/03/26 - 17:44

Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
Financial Data
Download

19/03/26 - 9:47

Diasorin signs strategic distribution agreement with McKesson Medical Surgical to expand access for the LIAISON NES molecular point‑of‑care platform (234.16 KB)
Other
Download

24/02/26 - 7:06

Diasorin introduces next-generation LIAISON QuantiFERON-TB Gold Plus II assay for the U.S. in partnership with QIAGEN (154.8 KB)
Products Immunodiagnostic
Download

03/02/26 - 12:13

Diasorin submits LIAISON NES Group A Strep molecular test to the U.S. FDA for 510(k) Clearance and CLIA Waiver (130.94 KB)
Products Molecular
Download

29/01/26 - 7:03

Diasorin has been granted De novo authorization in the U.S. for the First Fully Automated Laboratory Test for Hepatitis Delta Virus (HDV) on the LIAISON XL (128.56 KB)
Products Immunodiagnostic
Download

27/01/26 - 16:05

The Shareholders' meeting authorized the purchase of treasury shares, approved the amendment of art. 5 of the articles of association and authorized the cancellation of treasury shares. The Board approved the launch of the buyback plan. (120.91 KB)
Other
Download

26/01/26 - 7:09

Diasorin signs exclusive distribution agreement for the LIAISON NES® molecular point‑of‑care platform and the Flu A/B, RSV & Covid‑19 panel (131.63 KB)
Products Molecular
Download

23/01/26 - 17:49

Succession in the role of Group Chief Financial Officer of Diasorin. Alberto Donati appointed new Group Chief Financial Officer. (108.99 KB)
Other
Download

12/12/17 - 13:15

DiaSorin launches a new SIMPLEXA BORDETELLA DIRECT molecular test (426.89 KB)
Products Molecular
Download

29/11/17 - 19:30

Resignation of a Strategic Executive of the Company (233.58 KB)
Other
Download

09/11/17 - 14:15

GROWTH IN REVENUES AND NET PROFIT IN Q3 2017. STRONG FREE CASH FLOW GENERATION. 2017 GUIDANCE CONFIRMED (1001.87 KB)
Financial Data
Download

29/09/17 - 15:00

DiaSorin revises its guidance upwards for 2019 as a consequence of the completion of the acquisition of ELISA immunodiagnostic business portfolio and associated assets from SIEMENS (928.39 KB)
Financial Data
Download

29/09/17 - 14:15

DiaSorin completes the acquisition of the ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (332.93 KB)
Acquisition / Partnership
Download

21/09/17 - 12:45

DiaSorin earned CE-mark extending sample claims for DiaSorin Molecular's Simplexa HSV 1 & 2 kit (738.62 KB)
Products Molecular
Download

03/08/17 - 14:45

DiaSorin Group reports strong growth in revenues and profitability in Q2 2017 (1015.93 KB)
Financial Data
Download

28/07/17 - 14:45

DiaSorin launches 3 new primer pairs for use in molecular testing: PNEUMOCYSTIS JIROVECII, GROUP C STREPTOCOCCUS, and GROUP G STREPTOCOCCUS (427.51 KB)
Products Molecular
Download

25/07/17 - 21:00

DiaSorin to acquire ELISA immunodiagnostic business portfolio and associated assets from SIEMENS HEALTHINEERS (443.45 KB)
Acquisition / Partnership
Download

10/07/17 - 13:30

DiaSorin launches IAM CBFB-MYH11, completing the diagnostic test menu for molecular screening of acute myeloid leukemia by Q-LAMP (197.68 KB)
Products Molecular
Download

26/06/17 - 9:45

DiaSorin presents its 2017-2019 Industrial Plan (479.98 KB)
Financial Data
Download

23/06/17 - 9:30

DiaSorin and TECAN to collaborate in new platform development (755.46 KB)
Acquisition / Partnership
Download

22/06/17 - 19:45

DiaSorin and QIAGEN sign collaboration to expand Liaison test menu through adoption of select QIAGEN assays (430.67 KB)
Acquisition / Partnership
Download

23/05/17 - 11:45

DiaSorin launches the new Liaison SHBG test for the diagnosis of androgen-related disorders (735.43 KB)
Products Immunodiagnostic
Download

16/05/17 - 13:00

DiaSorin launches the new Liaison Androstenedione test for the evaluation of adrenal and gonadal functionality (429.25 KB)
Products Immunodiagnostic
Download

08/05/17 - 19:30

DiaSorin Group reports growth in revenues and profitability in the first quarter 2017, generating a relevant cash flow (984.86 KB)
Financial Data
Download

27/04/17 - 18:45

DiaSorin - Annual General Meeting 2016 (421.04 KB)
Financial Data
Download

21/04/17 - 18:45

DiaSorin receives authorization for the distribution of Zika IgM test in Europe (349.09 KB)
Products Immunodiagnostic
Download

06/04/17 - 18:00

DiaSorin receives FDA Emergency Use Authorization for the first, fully - automated Zika IgM test (376.16 KB)
Products Immunodiagnostic
Download

08/03/17 - 15:30

The Board of Directors approves the results for FY'16 (1.13 MB)
Financial Data
Download

21/02/17 - 11:30

DiaSorin launches its new Simplexa C. Difficile direct molecular test in the US market (430.86 KB)
Products Molecular
Download

26/01/17 - 12:45

DIASORIN LAUNCHES THE LIAISON FGF 23 TEST, THE FIRST INNOVATIVE AND FULLY AUTOMATED MARKER FOR CHRONIC KIDNEY DISEASE (140.98 KB)
Products Immunodiagnostic
Download
Price Sensitive

eMarket SDIR System and eMarket STORAGE
For the dissemination and the storage of Regulated Information, DiaSorin S.p.A. uses the eMarket SDIR circuit and the eMarket STORAGE mechanism (available at the address www.emarketstorage.it), managed by Teleborsa S.r.l., with registered office in Piazza di Priscilla, 4, Rome, Italy.